Investors

A lab technician marks a test tube in a lab
  • Creating value for our company, our shareholders and society

Investors

We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value.

Novartis Campus Entrance

Novartis Investors Event Calendar

View recent presentations and learn more about upcoming events.

Citi's 7th Annual IO Leadership Summit
February 19, 2019

Learn More

  • Share Data & Analysis

    Find information on Novartis share performance and dividend payouts.

    Learn More

  • Financial Data

    Review and download annual and quarterly reports, SEC filings and product sales information.

    Learn More

  • Shareholder Information

    Find information for shareholders and learn about our Annual General Meeting.

    Learn More

  • Company Overview

    Learn about Novartis leaders, corporate governance, our clinical pipeline and more.

    Learn More

Share Price

  • SIX

    90.08CHF

    as of Feb 15, 17:31 CET

    +0.98 (+1.10%)

  • NYSE

    89.88USD

    as of Feb 15, 16:02 EST

    +0.86 (+0.97%)

View stock performance
Featured Publications and Recent News
  • 2018 Q4 and Full Year results presentation preview

    Q4 and FY 2018 Results

    Presentation transcript

    Learn More
  • Novartis Media Release Q4 2018 Cover image

    Q4 and FY 2018 Results

    Media Release

    Download (PDF 0.3 MB)
  • Novartis Interim Fiancial Report Q4 2018 Cover image

    Q4 and FY 2018 Results

    Condensed Financial Report

    Download (PDF 0.5 MB)

  • Novartis Annual Reporting Suite

    Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

    Learn More
A pipette drops into test tubes

Novartis Clinical Pipeline

Our broad portfolio and strong pipeline help us offset the recurring impact of patent expirations for key products.

Explore Our Pipeline

Investor Relations Contacts

For questions about investor relations or the share registry, please contact our team.